Blue­print to pull Gavre­to in cer­tain mar­kets, shelve EGFR pro­grams as it fo­cus­es on Ay­vak­it launch

As Blue­print Med­i­cines braces it­self for a fu­ture with­out a ma­jor Roche col­lab­o­ra­tion, the Mass­a­chu­setts biotech is pulling its RET in­hibitor from cer­tain mar­kets and chop­ping sev­er­al can­cer drug can­di­dates in a pri­or­i­ti­za­tion ex­er­cise.

“Giv­en Blue­print Med­i­cines’ lack of glob­al in­fra­struc­ture in lung and thy­roid can­cer, the com­pa­ny has de­cid­ed to dis­con­tin­ue glob­al de­vel­op­ment and mar­ket­ing of GAVRE­TO in ter­ri­to­ries ex­clud­ing the U.S. and Greater Chi­na,” it wrote in a state­ment, adding that wind-down ac­tiv­i­ties will be­gin this quar­ter. Gavre­to is ap­proved in the Eu­ro­pean Union.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER